BR112020001785A2 - radiotraçador e compostos radioterapêuticos bimodais - Google Patents

radiotraçador e compostos radioterapêuticos bimodais Download PDF

Info

Publication number
BR112020001785A2
BR112020001785A2 BR112020001785-0A BR112020001785A BR112020001785A2 BR 112020001785 A2 BR112020001785 A2 BR 112020001785A2 BR 112020001785 A BR112020001785 A BR 112020001785A BR 112020001785 A2 BR112020001785 A2 BR 112020001785A2
Authority
BR
Brazil
Prior art keywords
bond
oligo
group
conjugate
sifa
Prior art date
Application number
BR112020001785-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Josef Wurzer
Hans-Jürgen Wester
Matthias Johannes Eiber
Original Assignee
Technische Universität München
Technische Universität München - Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität München, Technische Universität München - Klinikum Rechts Der Isar filed Critical Technische Universität München
Publication of BR112020001785A2 publication Critical patent/BR112020001785A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
BR112020001785-0A 2017-07-28 2018-07-30 radiotraçador e compostos radioterapêuticos bimodais BR112020001785A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
EP17183795.8 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (1)

Publication Number Publication Date
BR112020001785A2 true BR112020001785A2 (pt) 2020-09-29

Family

ID=59501286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020001785-0A BR112020001785A2 (pt) 2017-07-28 2018-07-30 radiotraçador e compostos radioterapêuticos bimodais

Country Status (21)

Country Link
US (4) US11413360B2 (https=)
EP (3) EP4424378A3 (https=)
JP (2) JP7059372B2 (https=)
KR (2) KR102752620B1 (https=)
CN (1) CN111132700B (https=)
AU (2) AU2018308699B2 (https=)
BR (1) BR112020001785A2 (https=)
CA (1) CA3071315A1 (https=)
DK (1) DK3658194T3 (https=)
EA (1) EA202090370A1 (https=)
ES (1) ES3011272T3 (https=)
FI (1) FI3658194T3 (https=)
HU (1) HUE070098T2 (https=)
IL (2) IL318092A (https=)
MX (2) MX2020000352A (https=)
NZ (1) NZ760537A (https=)
PL (1) PL3658194T3 (https=)
PT (1) PT3658194T (https=)
SG (1) SG11202000725WA (https=)
WO (1) WO2019020831A1 (https=)
ZA (1) ZA202000467B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE070098T2 (hu) * 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112021012110A2 (pt) 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
AU2021336987A1 (en) 2020-09-03 2023-04-06 Curium Us Llc Radiolabeling and formulation for scale up of 64Cu-dotatate
EP4023250A1 (en) 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
AU2022219543A1 (en) * 2021-02-15 2023-08-17 Technische Universität München Dual mode radiotracer and therapeutics
IL307381A (en) * 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer
MX2023013485A (es) * 2021-05-14 2023-12-07 Univ Muenchen Tech Radiofarmacos ligandos del receptor de la somatostatina y precursores de los mismos.
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4380629A1 (en) * 2021-08-05 2024-06-12 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
AU2023345654A1 (en) * 2022-09-20 2025-02-27 Technische Universität München Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
KR20250073273A (ko) 2022-09-23 2025-05-27 누클리디움 아게 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
AU2023379454A1 (en) * 2022-11-14 2025-05-29 Aktis Oncology, Inc. Decreased retention of miniproteins in kidney
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
JP2005519861A (ja) * 2001-07-27 2005-07-07 ターゲサム・インコーポレーテッド 治療剤及び撮像剤としての脂質構築物
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
RU2743781C2 (ru) * 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10800797B2 (en) * 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство

Also Published As

Publication number Publication date
US11413360B2 (en) 2022-08-16
US20260021211A1 (en) 2026-01-22
EP3658194A1 (en) 2020-06-03
MX2023007914A (es) 2023-07-13
CN111132700A (zh) 2020-05-08
IL272291B2 (en) 2025-06-01
IL272291A (en) 2020-03-31
US20200197545A1 (en) 2020-06-25
IL272291B1 (en) 2025-02-01
EP4424378A2 (en) 2024-09-04
ES3011272T3 (en) 2025-04-07
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
KR20240027896A (ko) 2024-03-04
EP4000640A1 (en) 2022-05-25
FI3658194T3 (fi) 2025-02-28
KR102752620B1 (ko) 2025-01-10
HUE070098T2 (hu) 2025-05-28
WO2019020831A1 (en) 2019-01-31
US12390540B2 (en) 2025-08-19
MX2020000352A (es) 2020-08-17
IL318092A (en) 2025-02-01
EA202090370A1 (ru) 2020-05-25
AU2024200440B2 (en) 2025-04-24
JP2020528461A (ja) 2020-09-24
PT3658194T (pt) 2025-02-13
PL3658194T3 (pl) 2025-09-15
EP3658194B1 (en) 2024-11-27
US20250121102A1 (en) 2025-04-17
CN111132700B (zh) 2022-12-13
JP2022101601A (ja) 2022-07-06
NZ760537A (en) 2026-01-30
AU2024200440A1 (en) 2024-02-08
JP7059372B2 (ja) 2022-04-25
DK3658194T3 (da) 2025-02-17
AU2018308699B2 (en) 2023-11-30
ZA202000467B (en) 2022-06-29
US20220370649A1 (en) 2022-11-24
AU2018308699A1 (en) 2020-01-23
SG11202000725WA (en) 2020-02-27
CA3071315A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
ES3011272T3 (en) Dual mode radiotracer and -therapeutics
JP7393485B2 (ja) 前立腺特異的膜抗原(psma)の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
CN113573743B (zh) 癌症诊断成像剂
CN111491668B (zh) 一种含有与铅或钍放射性核素连接的psma靶向化合物的络合物
BR112020011727A2 (pt) ligantes de psma para imageamento e endorradioterapia
BR112021014933A2 (pt) Radiomarcador de modo duplo de ligação a psma e terapêutica
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
EA052134B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]